Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00958334 · ClinicalTrials.gov registry record · Phase 2

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

A Phase 2 study of Uterine Fibroids, sponsored by Repros Therapeutics.

Completed
Registry status
Phase 2
Development phase
65
Enrollment target
11
Study locations

NCT00958334: Completed Phase 2 study of Uterine Fibroids, sponsored by Repros Therapeutics.

NCT00958334 is a Phase 2 study of Uterine Fibroids that has completed, run by Repros Therapeutics. The registered enrollment target is 65 participants, below the 238-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (73% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00958334, a Phase 2 study of Uterine Fibroids, has completed, sponsored by Repros Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
65 participants
Enrollment target
11
Study locations

Study Summary

ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258) to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study.

Primary Outcome

An ODI is defined as a time period of less than 3 months during which a return to menses occurs. All statistical endpoints will use the baseline of ZPU-003 Ext for 14-month data and baseline of ZPU-003 for 17-month data.

Conditions Studied

Interventions

  • DRUG Proellex®

Study Locations (11)

Arizona

  • Women's Health Research - Phoenix
  • Arizona Wellness Centre for Women - Phoenix

California

  • Medical Centre for Clinical Research - San Diego
  • Women's Health Care, Inc. - San Diego

Texas

  • Advances in Health Inc. - Houston
  • Obstetrical & Gynecolgical Associates, PA (OGA) - Houston

Colorado

  • Downtown Women's Health Care - Denver

Florida

  • Insignia Clinical Research (Tampa Bay Women's Center) - Tampa

Nevada

  • Affiliated Clinical Research, Inc. - Las Vegas

South Carolina

  • SC Clinical Research Center - Columbia

Washington

  • Women's Clinical Research Centre - Seattle

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2006-09-07
Est. Completion 2008-10-15
Phase Phase 2
Repros Therapeutics

50 total trials

What the finished NCT00958334 record still lists

NCT00958334 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 238-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Uterine Fibroids appearing as the primary indexed condition, and to 1 intervention - of which Proellex® is the first listed.

NCT00958334 lists 11 locations in 8 states (Arizona, California, Texas).

Frequently Asked Questions

What is clinical trial NCT00958334 about?

NCT00958334 is a clinical study titled "Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003". ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258) to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study.

What is the current status of trial NCT00958334?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2006-09-07. Estimated completion is 2008-10-15.

What conditions does trial NCT00958334 study?

This clinical trial studies the following conditions: Uterine Fibroids.

What interventions are being tested in trial NCT00958334?

The interventions under investigation include: Proellex® (DRUG).

Who is sponsoring clinical trial NCT00958334?

This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00958334 being conducted?

This trial has 11 study locations across Arizona, California, Colorado, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uterine Fibroids

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00958334's enrollment target sits among peer trials

65 5th of 10 higher than 6 of 10 other Uterine Fibroids trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Uterine Fibroids trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00958334, the US trial registry maintained by the National Library of Medicine. NCT00958334 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.